Skip to main content

Table 3 Summary of clinical characteristics of patients without del[5q] on MC who received lenalidomide (N = 42)

From: Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

Diagnosis (No. of Patients)    
MDS   31  
  RA   5
  RARS   13
  RCMD   1
  RAEB-1   4
  RAEB-2   7
  MDS-U   1
MDS/MPN   7  
  CMML-1   2
  CMML-2   2
  MDS/MPN-U   3
PMF   2  
sAML   2  
Age (years old)    
  Median (Range)   70 (46-83)
Sex (No. of Patients)    
  M   28
  F   14
IPSS (No. of Patients)    
  LOW   12
  INT-1   11
  INT-2   7
  HIGH   1
  not indicated   11
Duration of MDS (months)
  Median (Range)   15 (0-118)
Previous Therapies
  Yes   27
  No   15
Transfusion dependence (No. of Patients)
  Yes   30
  No   12
Neutropenia (< 1.5 × 109/μ) (No. of Patients)
  Yes   5
  No   37
Thrombocytopenia (< 100 × 109) (No. of Patients)
  Yes   12
  No   30
Therapy (No. of Patients)
   LEN (5-10 mg/day) alone    30
   LEN high dose (50 mg/day)    1
  LEN/AZA   11
Duration of LEN therapy (months)
  Median (Range)   5 (0-76)
Response to therapy (No. of Patients)
  CR   9
  PR   3
  HI   10
  NR   16
  NE   4
  1. Abbreviation: MDS myelodysplastic syndromes; RA refractory anemia; RARS refractory anemia with ring sideroblasts; RCMD refractory cytopenia with multilineage dysplasia; RAEB refractory anemia with excess blasts, MDS-U MDS unclassifiable; MDS/MPN MDS/myeloproliferative neoplasm; CMML chronic myelomonocytic leukemia; MDS/MPN-U MDS/MPN unclassifiable; PMF primary myelofibrosis; sAML secondary acute myeloid leukemia; M male; F female; LEN lenalidomide; LEN/AZA LEN/azacitidine; CR complete response; PR partial response; HI hematological improvement; NR no response; NE not evaluated.